Guardant Health (GH) vs Humana (HUM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Guardant Health (GH) has outperformed Humana (HUM) over the past year, gaining 165.3% versus a gain of 34.3%. Over five years, GH leads with a +65.7% price change compared with -10.1% for HUM. Humana is the larger company by market cap ($47.61 billion vs $22.59 billion), about 2.1 times the size, while Guardant Health is growing revenue faster (+32.9% vs +10.1%).
Humana pays a dividend yielding 0.89%, while Guardant Health does not currently pay one. Humana converts more of its revenue into profit, with a net margin of 0.9% versus -42.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GH | HUM |
|---|---|---|
| Share price | $168.33 | $396.51 |
| Market cap | $22.59B | $47.61B |
| 1-day change | -1.38% | -1.92% |
| YTD return | +64.80% | +54.81% |
| 1-year return | +165.34% | +34.30% |
| 5-year return | +65.68% | -10.09% |
| P/E ratio (TTM) | — | 37.48 |
| Forward P/E | — | 23.90 |
| EPS (TTM) | $-3.50 | $10.58 |
| Dividend yield | 0.00% | 0.89% |
| Annual dividend | $0.00 | $3.54 |
| Revenue (latest FY) | $982.02M | $129.66B |
| Revenue growth (YoY) | +32.88% | +10.11% |
| Net income (latest FY) | $-416.28M | $1.19B |
| Gross margin | 64.46% | — |
| Operating margin | -44.53% | 2.09% |
| Net margin | -42.39% | 0.92% |
| 52-week high | $191.05 | $428.88 |
| 52-week low | $61.00 | $163.11 |
| Distance from 52-week high | -11.89% | -7.55% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +18.72% | +6.87% |
| Average volume | 2.01M | 1.23M |
| Shares outstanding | 134.20M | 120.08M |
| Employees | 2,490 | 67,060 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Humana is about 2.1 times larger than Guardant Health by market value ($47.61B vs $22.59B).
- GH has outperformed HUM by 131.0 percentage points over the past year.
- Humana is more profitable, keeping 0.9 cents of every revenue dollar as net income versus -42.4 cents for Guardant Health.
- Guardant Health grew revenue faster in its latest fiscal year (+32.88% vs +10.11%).
About Guardant Health
GH stock →Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights.
Health Care · Medical Specialities · 2,490 employees
About Humana
HUM stock →Humana Inc. provides medical and specialty insurance products in the United States.
Health Care · Medical Specialities · 67,060 employees
GH vs HUM FAQ
Which is bigger, Guardant Health or Humana?
Humana (HUM) is larger, with a market capitalization of $47.61B compared with $22.59B for Guardant Health (GH).
Which stock has performed better over the past year, GH or HUM?
GH returned +165.34% over the past 12 months, compared with +34.30% for HUM (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Guardant Health or Humana?
Humana pays a dividend yielding 0.89%, while Guardant Health does not currently pay a regular dividend.
Are Guardant Health and Humana in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.